ERBB2 and breast carcinoma: The identification of the intrinsic molecular breast cancer subtypes (HER2 + , luminal A, luminal B, basal-like and normal-like) based on gene expression patterns [98, 99] and the prognostic gene signatures that separated low from high-risk breast cancers [100–102] initiated an era of high-throughput studies on the molecular profiles of breast cancers.